In last trading session, Actinium Pharmaceuticals Inc (AMEX:ATNM) saw 0.3 million shares changing hands with its beta currently measuring -0.18. Company’s recent per share price level of $1.29 trading at -$0.1 or -7.19% at ring of the bell on the day assigns it a market valuation of $40.24M. That closing price of ATNM’s stock is at a discount of -693.8% from its 52-week high price of $10.24 and is indicating a premium of 20.16% from its 52-week low price of $1.03. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.45 million shares which gives us an average trading volume of 576.09K if we extend that period to 3-months.
For Actinium Pharmaceuticals Inc (ATNM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.29 in the current quarter.
Actinium Pharmaceuticals Inc (AMEX:ATNM) trade information
Upright in the red during last session for losing -7.19%, in the last five days ATNM remained trading in the red while hitting it’s week-highest on Monday, 03/31/25 when the stock touched $1.29 price level, adding 28.2% to its value on the day. Actinium Pharmaceuticals Inc’s shares saw a change of 2.38% in year-to-date performance and have moved -28.73% in past 5-day. Actinium Pharmaceuticals Inc (AMEX:ATNM) showed a performance of 13.16% in past 30-days. Number of shares sold short was 2.21 million shares which calculate 14.51 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 4.95 to the stock, which implies a rise of 73.94% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 24.26. It follows that stock’s current price would drop -210.08% in reaching the projected high whereas dropping to the targeted low would mean a loss of -210.08% for stock’s current value.
And 4 analysts are in estimates of company making revenue of 8.9M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 21.99% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 23.82% while estimates for its earnings growth in next 5 years are of 6.04%.
Actinium Pharmaceuticals Inc (AMEX:ATNM)’s Major holders
Insiders are in possession of 1.79% of company’s total shares while institution are holding 29.26 percent of that, with stock having share float percentage of 29.80%. Investors also watch the number of corporate investors in a company very closely, which is 29.26% institutions for Actinium Pharmaceuticals Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at ATNM for having 1.88 million shares of worth $13.88 million. And as of 2024-06-30, it was holding 6.23 of the company’s outstanding shares.
The second largest institutional holder is GEODE CAPITAL MANAGEMENT, LLC, which was holding about 0.67 million shares on 2024-06-30. The number of shares represents firm’s hold over 2.2134 of outstanding shares, having a total worth of $4.93 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 938.63 shares of worth $1.21 million or 3.01% of the total outstanding shares. The later fund manager was in possession of 775.93 shares on Feb 28, 2025 , making its stake of worth around $1.0 million in the company or a holder of 2.49% of company’s stock.
